

Effects of black chokeberry (*Aronia melanocarpa*) supplementation on oxidative stress, inflammation, and gut microbiota: a systematic review of human and animal studies

Sabina Kaczmarczyk^{1*}, Hanna Dziewiecka¹, Marta Pasek¹, Joanna Ostapiuk-Karolczuk¹, Anna Kasperska¹, Anna Skarpańska-Stejnborn¹

¹Department of Biological Sciences, Faculty of Sport Sciences in Gorzów Wielkopolski, Estkowskiego13, University of Physical Education, Poznań, Poland.

***Corresponding author:** Sabina Kaczmarczyk, Department of Biological Sciences, Faculty of Sport Sciences in Gorzów Wielkopolski, Estkowskiego13, University of Physical Education, Poznań, Poland. E-mail: iskra@awf.poznan.pl

Health benefits of chokeberries

Keywords: chokeberries; health benefits; intestinal parameters; antioxidant;



This peer-reviewed article has been accepted for publication but not yet copyedited or typeset, and so may be subject to change during the production process. The article is considered published and may be cited using its DOI

10.1017/S0007114524002976

The British Journal of Nutrition is published by Cambridge University Press on behalf of The Nutrition Society

Abstract:

The scientific literature indicates that chokeberry is widely used as a supplement to support the maintenance of the body's homeostasis by reducing inflammation and oxidative stress. In recent years, positive effects of chokeberry on intestinal parameters have also been observed. Oxidative stress, inflammation, and according to recent reports, also the gut microbiome are closely related to the overall well-being and health of the population. This study, therefore, attempts to summarize all the health benefits of black chokeberry supplementation. This study was registered in PROSPERO (International Prospective Register of Systematic Reviews) under registration number CRD42023395969. Additionally, the systematic review was conducted following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) method. Electronic databases were searched in Web of Science, Pubmed, Scopus, and EBSCO using the following combination of the words “chokeberry or aronia” and “inflammation or oxidative stress or microbiota or microbiome or permeability or gut.” Ultimately, 57 studies were summarized in the review. Data analysis showed that black chokeberry has a positive effect on the reduction of inflammation, oxidative stress, and intestinal microflora, but the size of the changes varies and depends on many variables. Therefore, the researchers concluded that the compounds found in black chokeberry play a pivotal role in maintaining the overall balance within the system. This is a crucial consideration given the tendency for disturbances in organismal homeostasis to accompany disease processes and various disorders. However, further research is necessary to elucidate the mechanisms and optimize its use fully.

Abbreviations

8-OHdG: 8-hydroxy-2'-deoxyguanosine; ACE: abundance-based coverage estimator; AMPK: adenosine 5'-monophosphate (AMP)-activated protein kinase; b.w.: body weight; CAT: catalase; CNS: central nervous system; ChaO1: total number of species in a sample; COX-2, cyclooxygenase-2; CRP: C-reactive protein; F/B ratio: Firmicutes/Bacteroides ratio; FoxO: transcription factor; GPx: glutathione peroxidase; GR: glutathione reductase ; GSH: reduced glutathione; GSH-Px: glutathione peroxidase; GSH-r: glutathione reductase ; GSSG: oxidized glutathione; GST: glutathione transferases; H₂O₂: hydrogen peroxide; IFN- γ : Interferon gamma; IgA: immunoglobulin A; IgG: immunoglobulin G; IgM: immunoglobulin M; IL-1, interleukin-1; IL-17: interleukin 17; IL-1 β : interleukin 1 β ; IL-6: interleukin 6; iNOS: inducible nitric oxide synthase ; Keap1: kelch-like ECH-associated protein 1; LPO: lipid

peroxides; MCP-1: monocyte chemoattractant protein-1; MDA: malondialdehyde; mTOR: mammalian rapamycin target protein; NADPH: nicotinamide adenine dinucleotide phosphate; NF- κ B nuclear factor kappa-B; NOS: nitric oxide synthase; Nrf2: nuclear related factor-2; OH: hydroxyl groups; P53: tumor protein P53; PCoA: Principal coordinate analysis ; PGC-1 α : peroxisome proliferator-activated receptor gamma coactivator 1-alpha; PGE2: prostaglandin E2; PI3HO⁻¹: heme oxygenase-1; PI3K: P-phosphatidylinositol-3-hydroxykinase; ROS: reactive oxygen species; SIRT1: sirtuin 1; SOD: superoxide dismutase; TAC: total antioxidant capacity; T-AOC: total antioxidant capacity; TAS: total antioxidative status; TBARS: thiobarbituric acid reactive substances; TGF- β 1, transforming growth factor- β 1; TLR4: Toll-like receptor 4 ; TNF- α : tumor necrosis factor alpha; TOS: total oxidative status

1. Introduction

In the early 20th century, the prevailing trend was to study foods rich in phytochemicals and evaluate their bioactivity. Among all the berries, black chokeberry, *Aronia melanocarpa*, gained the most popularity as it is one of the richest plant sources of polyphenols⁽¹⁾. Polyphenols, particularly anthocyanins, exhibit strong antioxidant properties. The literature indicates that the antioxidant capacity of chokeberry juice is four times higher than in cranberry, blueberry, or red grape juice⁽²⁾.

Within the bioavailability framework, contemporary research has elucidated that the constituents of chokeberry are detectable in systemic circulation and excreted in urine at nanomolar concentrations. Furthermore, studies have identified glucuronidation and methylation as primary metabolic pathways in the biotransformation of chokeberry-derived anthocyanins. It is noteworthy that the bioavailability of these anthocyanins is significantly modulated by extensive metabolism conducted by gut microbiota in the colon. This complex metabolic process produces a diverse spectrum of low molecular weight phenolic metabolites, which exhibit enhanced bioavailability and superior absorption rates⁽³⁾.

According to the literature, black chokeberry *Aronia melanocarpa* exhibits strong antioxidant properties. The mechanisms underlying these properties are multifaceted, involving the enhancement and protection of enzymes such as paraoxonase, superoxide dismutase, and glutathione. Additionally, chokeberry inhibits the activity of several key enzymes involved in oxidative and inflammatory processes. Specifically, it reduces the activity of inducible nitric oxide synthase (iNOS), which is responsible for producing nitric

oxide in response to inflammatory stimuli and can contribute to oxidative stress and tissue damage. It also inhibits NADPH oxidase, an enzyme complex that generates reactive oxygen species (ROS) and plays a crucial role in the body's defense mechanism and pathology of various diseases. Furthermore, chokeberry suppresses lipoxygenase, an enzyme involved in the polyunsaturated fatty acids metabolism to form pro-inflammatory leukotrienes. By inhibiting these enzymes, chokeberry helps to mitigate oxidative stress and inflammation, contributing to its overall protective effects against various diseases ^(2,4). As other research shows, chokeberry anthocyanins also demonstrate protective effects against the oxidation of α - and γ -tocopherol ⁽⁵⁾. Research has shown that *Aronia melanocarpa* constituents can accumulate at the lipid bilayer-aqueous phase interface in erythrocyte membranes. Their localization within the hydrophilic region of the membrane creates a protective barrier against free radicals, thereby enhancing the effectiveness and safety of these antioxidants ⁽⁶⁾.

Anthocyanins in black chokeberry also play a significant role in modulating inflammation. This regulatory effect is attributed to their ability to bind iron and regulate various immune system components involved in inflammatory processes ⁽⁷⁾. The anti-inflammatory properties of black chokeberry are intricately linked to the enhancement of the human immune response. This involves the suppression of pro-inflammatory cytokines and the release of anti-inflammatory cytokines. The antiviral and antimicrobial properties of chokeberry additionally contribute to its anti-inflammatory effects ⁽⁸⁾.

Scientific evidence supports aronia supplementation's impact on clinical and sporting populations. This is mainly related to the activity of anthocyanin compounds, which have been shown to have strong antioxidant, anti-inflammatory, and cardioprotective properties ^(1,9). In individuals with metabolic disorders, such as diabetes, obesity, and cardiovascular diseases, oxidative stress, and chronic inflammation are critical factors contributing to the progression of these conditions. Research indicates that aronia supplementation can mitigate these pathological processes by reducing oxidative stress markers and inflammatory cytokines, thereby improving metabolic parameters such as lipid profiles, blood glucose levels, and insulin sensitivity ⁽¹⁰⁻¹²⁾. Moreover, in healthy individuals, particularly athletes, the high-intensity physical exertion associated with training and competition leads to an increased production of reactive oxygen species (ROS), which can result in oxidative damage to cells and tissues. The antioxidant capacity of aronia can help neutralize these ROS, thereby reducing exercise-induced oxidative stress. This can potentially enhance recovery, reduce muscle damage, and improve overall athletic performance. The anti-inflammatory effects of aronia may also contribute to faster recovery times and reduced post-exercise soreness ^(6,13)

Recent studies have established a connection between dysbiosis of the human gut and a variety of diseases, including obesity, diabetes, depression, and irritable bowel syndrome. The gut microbiome plays a critical role in maintaining the integrity of the intestinal epithelial barrier, which is essential for the functional maturation of the gut immune system. Disruption of homeostasis in the gut can lead to systemic effects due to the leakage of the epithelial wall, allowing endotoxins and bacteria to enter systemic circulation and trigger endotoxemia and inflammatory responses. Polyphenols have been identified as modulators of the microbiome composition ⁽¹⁴⁾. There likely exists a bi-directional relationship between the human gut microbiome and polyphenols, mirroring the interaction between polyphenols and the microbial population in the root systems of plants ⁽¹⁵⁾. *Aronia melanocarpa*, a rich source of polyphenols, may have consequently a significant impact on the human gut microbiome, promoting gut health and potentially mitigating the risks associated with gut dysbiosis.

Therefore, this study focuses on a detailed investigation through literature, including all available articles from databases, to explore the impact of black chokeberry on oxidative stress, inflammation, and intestinal parameters in both animal models and human subjects. Recognizing the existence of prior research exploring the impacts of black chokeberry on these physiological factors, our systematic review distinguishes itself as the initial effort to amalgamate and integrate findings across these realms, providing a comprehensive elucidation of the biological effects of black chokeberry on living organisms. Furthermore, this comprehensive aggregation of research articles enables a detailed analysis of results attained to date, thereby identifying areas warranting further exploration and analysis.

This systematic review will address whether and how black chokeberry affects biomarkers of oxidative stress, inflammation, and intestinal parameters, and whether interactions exist between these biomarkers. Although there is ample evidence supporting the positive effects of chokeberry on oxidative stress, inflammation, and intestinal parameters, the hypothesis carries some uncertainty. It should be noted that studies are conducted on different cohorts (animals, healthy individuals, patients, athletes), the supplement comes in various forms (extract, juice, fresh fruit) and contains different concentrations of active compounds (anthocyanins, polyphenols). Additionally, the dose and duration of supplementation vary, and chokeberry is expected to affect various physiological and pathological states (high oxidative stress, inflammation, post-exercise recovery), each

characterized by distinct mechanisms of action. Therefore, it is important to bear these limitations in mind when interpreting the results.

2. Materials and Methods

2.1. Search Strategy

This systematic literature review focused on the health benefits of black chokeberry (*Aronia melanocarpa*) supplementation. Due to the relatively low number of RCTs, animal model studies were also included in the review. For better interpretation and clarity, human and animal data were presented separately. The systematic review was conducted according to PRISMA (Preferred reporting items for systematic reviews and meta-analyses) principles. This study was registered with PROSPERO (International Prospective Register of Systematic Reviews) under registration number CRD42023395969. Electronic database searches were performed on the Web of Science, Pubmed, Scopus, and EBSCO. The search strategy for RCTs and in vivo studies were the same by combining the words ‘aronia OR chokeberry’ AND ‘inflammation OR oxidative stress OR microbiota OR microbiome OR gut permeability OR gut’. The reference list of retrieved literature reviews was then manually searched for find potential articles that could be included in the systematic review. The study used a protocol involving simultaneous searches and separate presentation of results. This was similarly performed by Groulx et al, ⁽¹⁶⁾. No restrictions on publication date or study type were applied to any search strategy. The search included original papers in English published before 01.05.2024.

2.2. Inclusion and Exclusion Criteria

The inclusion criteria used in the study:

- Articles in English language
- Participants: people of all ages, animals only in vivo
- Supplementation with black chokeberry in any form (i.e. juice, extract, diet) and any dose (if the exact dose used in the study is given),
- Published in full in a peer-reviewed journal
- Randomized controlled trials and clinical trials concerns RCTs

- Only the level 1 OCEBM scale (Table 1) concerns RCTs

The exclusion criteria used in the study:

- In vitro testing
- The use of another kind of chokeberry (e.g., chokeberry "Viking")
- Observational studies, meta-analysis, systematic review,
- Articles in not English language

>inserttable1<

2.3. Data Extraction

Data was first evaluated by two investigators (S. K and H. Dz) and then was checked independently by two other supervisors (A. S-S and A. K). All articles were searched using the keywords. After that, all replicas were removed, and article abstracts were analyzed based on the eligibility criteria. Finally, full texts of articles that met the eligibility criteria were analyzed. Each publication selected for the review was critically evaluated. All articles' full texts were available online. Independently extracted data from studies were entered into two tables (for the RCT and the animal model).

The table for the RCT studies included study information such as: first author and year of publication, OCMB level, research and control group characteristics and size, type of supplement, dose, duration of supplementation, and direction of change in inflammatory, oxidative stress, or gut microbiota.

The table for in vivo studies included information such as first author and year of publication, characteristics and size of the model and control group, type of supplement, dose, duration of supplementation, and direction of change in inflammatory, oxidative stress, or gut microbiota.

2.4. Quality Assessment

Following the analyses described above, the level of evidence in the RCTs was assessed by four independent reviewers (H. Dz., A. K., S. K., M. P.) using the 2011 Oxford Center for Evidence-Based Medicine (OCEBM) method, developed by an international group of researchers involving clinicians, patients and investigators (Table 1). The OCEBM method enables the rapid identification of the best evidence, encouraging clinicians, researchers, and patients to autonomously evaluate the evidence.

Subsequently, a bias analysis of human studies was performed by two investigators (H. Dz., M. P.) using the latest version of the Cochrane Collaboration Risk-of-Bias Tool (Table 2), which is used in randomized trials⁽¹⁷⁾. Studies were screened in five areas: bias due to the randomization process, bias due to deviations from the intended intervention, bias due to missing outcome data, bias in the outcome measure, and bias in the choice of reported outcomes. This tool allows the investigator to classify each domain as high risk, of some concern, or low risk. Some concern was found mainly in the randomization process.

Analysis of bias of animal studies using the SYRCLE's ROB tool (Table 3) was performed by two investigators (M.P., S.K.). The SYRCLE tool is based on the Cochrane Collaboration Tool but contains 10 entries. These entries are related to 6 types of bias: selection bias, performance bias, detection bias, attrition bias, reporting bias, and other biases⁽¹⁸⁾.

2.5. Statistical Analyses

The quantitative data were presented in tables, without further statistics. The studies presented data in different formats and/or with different structures. Because of low heterogeneity in the studies (different cohorts, physiological states, supplement forms, doses, and supplementation times), it was not possible to extract data for meta-analysis for statistical comparison. The summary tables contain data extracted from included studies containing participants' characteristics, doses, duration of supplementation, and outcomes.

3. Results

The literature searches identified 960 potential articles. After removing 536 duplicates, 424 records were subjected to article title and abstract screening. Subsequently, the full texts of 120 articles were meticulously examined, including 57 articles in the review (Figure 1). These articles have been categorized into two tables: Table 4 comprises studies conducted utilizing animal models, while Table 5 encompasses studies involving human subjects.

Studies conducted on an animal model

In Table 4 the total number of manuscripts is forty-five. The size of the groups is less than 50 in twenty-one articles^(19–40). The group size in the range of 50-100 is fourteen articles^(41–54). More than a group size of more than 100 participants is found in seven articles^(55–61). Moreover, twelve articles were about females^(31,37,40,42,50,52,53,55,56,58,60,61). Four articles^(23,29,39,59) lack clearly defined gender of animals, while two articles discuss both males and females^(32,38). In other papers, the research was performed with males. Markers of oxidative

stress were analyzed in thirty-six articles^(19–24,26–29,31,32,36,39–43,43–50,52–61), while indicators of inflammation were determined in seventeen studies^(22,25,27,33,37,40–48,54,62,63). Changes in gut microbiota were studied in eight articles^(30,34,36,38,40,42,43,51).

Studies conducted with humans

In Table 5, the total number of articles is twelve. The group size is less than 50 in nine articles^(6,7,11,13,64–69). A group size of more than 50 participants occurs in three articles^(12,68,70). Five articles involved only men^(6,7,13,65,70), and the remaining six manuscripts involved both sexes^(11,12,64,66–68). One article focused on women⁽⁶⁹⁾. In five articles, the participants were athletes^(6,7,13,65,66), the other two manuscripts were about patients^(11,64), and the remaining articles refer to healthy people^(12,67–70). Markers of oxidative stress were analyzed in nine articles^(6,7,11,13,64–68). Indicators of inflammation were analyzed in five manuscripts^(6,7,13,67,68), while intestinal parameters were indicated in only three^(12,69,70).

Effect of chokeberry on prooxidant-antioxidant balance parameters - human.

Of the human studies, eight analyzed markers were related to prooxidant-antioxidant balance i.e., TBARS, GSH, SOD, CAT, TAC, GPx, GSSG, MDA. Reduced levels of lipid peroxidation expressed as TBARS were observed in five studies^(7,11,64–66). Only one experiment showed no change in TBARS concentration⁽⁷⁾. One manuscript analyzed GSH levels and showed a decrease in concentration⁽⁶⁸⁾. The value of SOD was analyzed in four studies^(64,65,67,68). In two manuscripts, no changes in SOD levels were observed^(67,68). One article showed an increase or no change depending on the length of supplementation⁽⁶⁴⁾, and one manuscript showed a decrease in SOD levels⁽⁶⁵⁾. As for CAT, in one paper there was a decrease in CAT concentration⁽⁶⁴⁾. No change in CAT values was observed in two articles^(67,68). Only three manuscripts analyzed the level of TAC values^(6,7,13). Two exhibits showed an increase in TAC values^(6,13), and the other showed no change⁽⁷⁾. The GPx index was analyzed in three papers^(65,67,68). Two manuscripts showed a decrease in levels^(65,68). One paper showed no change in values. The GSSG parameter was analyzed in only one article, where a reduction in values was observed⁽⁶⁸⁾. Similarly, the biomarker MDA was analyzed in only one manuscript where no changes were shown⁽⁶⁸⁾.

Effect of chokeberry on inflammation – human.

Inflammation was analyzed in five papers. IL-6 levels were analyzed in five papers^(6,7,13,67,68). In three manuscripts, no changes were observed^(6,7,67), while one experiment showed an increase in IL-6 levels⁽⁶⁸⁾ and one study showed a decrease⁽¹³⁾. TNF- α levels were analyzed

in two manuscripts^(6,67). One paper showed no change⁽⁶⁷⁾, and one paper observed a decrease in levels⁽⁶⁾. Myoglobin levels were analyzed in only one manuscript, where no changes were shown⁽⁷⁾. IL-1 β levels were studied in one study, which showed no change⁽⁶⁷⁾. The CRP biomarker was analyzed in one manuscript and no changes were observed⁽⁶⁷⁾.

Effect of chokeberry on gut health – human

There were only three articles on humans considering gut health^(12,69,70). Nevertheless, alpha and beta diversity remained unchanged^(12,70), *Bacteroides* and its representative *Bacteroides xylanisolvens* increased^(12,70), *Haemophilus parainfluenzae* decreased in one study⁽¹²⁾.

Effect of chokeberry on prooxidant-antioxidant balance parameters - an animal model

In thirty-six studies conducted on animal models, the effects of chokeberry on markers of anti-oxidation-peroxidation balance were measured, i.e., GSH, GSH-Px, SOD, MDA, O₂, H₂O₂, HO⁻¹, TBARS, CAT, GPx, GR, TAS, ROS, TAOC, Nrf2, TOS. The GSH index was analyzed in nineteen manuscripts^(19,20,29,31,32,32,39,40,43,44,46,49,52,53,60,61). Eight articles showed an increase in the biomarker^(23,29,31,32,43,44,46,49), while the rest showed no change^(19,20,39,40). In the seven studies, the change varied at different time points^(50,52,53,55,58,60,61). The GSH-Px parameter was analyzed in six studies, and all papers observed an increase in its concentration^(21,23,41,42,45,47). The SOD biomarker was analyzed in twenty-nine papers. In eleven articles, an increase was observed^(21,34,41,43–47,56,57,59). Eight manuscripts showed no change^(22,26,28,31,36,39,40,42), while three articles showed a decrease in SOD levels^(20,24,29). In the seven studies, the change varied at different time points^(50,52,53,55,58,60,61). The MDA index was determined in seventeen manuscripts, with thirteen articles showing a decrease^(21,23,27,34,36,40,41,43,44,47,56,59) and the rest showing no change^(19,28,45,48). The TBARS biomarker was determined in seven manuscripts. Its reduction was observed in five articles^(20,22,24,31,44), while no change was observed in two^(39,49). The parameters H₂O₂ were determined in six articles. A reduction was observed in three articles^(31,55,57). In the three studies, the change varied at different time points^(50,60,61). In one study, an increase in the concentration of HO⁻¹⁽³⁴⁾ was observed, and in another, a decrease⁽⁵⁴⁾. The CAT biomarker was studied in twenty-three manuscripts. Eleven articles showed an increase in concentration^(22,26,31,34,41,44,47,53,57,59,61), seven studies showed no change^(20,24,28,36,39,40,42), and in five articles the change varied at different time points^(50,52,55,58,60). In seventeen manuscripts, the GPx index was determined. Most of the six studies showed no change^(20,24,26,28,39,60), while the remaining articles showed an increase^(22,29,36,50,55–58). In the three studies, the change varied

at different time points ^(52,53,61). The GR biomarker was analyzed in seven manuscripts. No changes were observed in two studies ^(20,22). The level was lower in one manuscript ⁽⁵⁷⁾ and in four studies the change varied at different time points ^(55,58,60,61). The TOS and TAS index were determined in four studies with the change varying at different points in time ^(50,57,60,61). The TAOC biomarker was analyzed in four manuscripts. Three papers showed an increased concentration ^(23,40,56), while two more showed no change ⁽⁴²⁾. Nrf2 was determined in four studies and an increase in its concentration was observed in all of them ^(21,34,56,59).

Effect of chokeberry on inflammation - an animal model

Indicators of inflammation were determined in seventeen manuscripts. TNF- α was the most frequently analyzed biomarker, in eight out of ten articles a reduction was observed ^(25,33,37,40,46,47,54,63), while one study showed no change ⁽²²⁾. One study observed no change before renal injury and a reduction after renal injury ⁽⁴⁴⁾. IL-6 was the second most frequently analyzed biomarker, with eight manuscripts showing a reduction ^(25,37,40,41,46–48,54). One study showed no change before kidney injury and a reduction after kidney injury ⁽⁴⁴⁾. IL-1 β levels were determined in five manuscripts. Four papers showed its reduction ^(25,37,40,47), while one paper observed no change before kidney injury and a reduction after kidney injury ⁽⁴⁴⁾. NF-kB factor was also analyzed in four studies. In each study, the results indicated a decrease in concentration ^(25,27,33,34). IL-10 was determined in three articles, with two papers showing a reduction ^(40,47) and one showing no change ⁽⁴⁸⁾. IL-1 was determined in three manuscripts and reductions were observed ^(45,46,54). The COX2 index in two articles was reduced ^(45,46). Similarly, the TGF- β 1 index was determined in two articles ^(22,45).

Effect of chokeberry on gut health – an animal model

Eight research teams checked gut health in an animal model ^(30,34–36,38,40,43,51). Alpha diversity was raised in three studies ^(38,42,51) and remained unchanged in three studies ^(30,40,51); in one study this indicator decreased ⁽⁴³⁾. Four studies found an increase in *Bacteroides* and *Bacteroidetes* ^(30,34,40,51). The *Firmicutes* to *Bacteroides* ratio are inconclusive; it decreased in two studies ^(30,51). Phyla *Verumicrobia* raised in two studies ^(30,51); also, *Prevotella* increased in three studies ^(30,40,51).

4. Discussion

Effects of black chokeberry on prooxidant-antioxidant balance parameters

After a thorough review of the available research, it can be concluded that compounds derived from chokeberry offer significant efficacy in reducing oxidative stress. This reduction is associated with the scavenging of free radicals, inhibition of lipid peroxidation, and modulation of both enzymatic and non-enzymatic antioxidant activities ^(21,41,43,44). Nevertheless, the interplay among specific biomarkers fluctuates across studies conducted on diverse cohorts, employing varying supplementation doses and durations. For instance, Zhao et al. administered chokeberry extract at doses of 200 and 400 mg/kg b.w./day to mice with thioacetamide (TAA)-induced liver fibrosis over 4 weeks. Their findings indicated an increase in glutathione (GSH) levels, associated with elevated superoxide dismutase (SOD) levels and a decrease in malondialdehyde (MDA) levels (see Table 4) ⁽⁴³⁾. Li et al. also obtained analogous findings, by administering a blend of anthocyanins at a dose of 50 mg/g body weight, equivalent to 25 ml/g body weight, twice a day for 14 days to mice afflicted with kidney ischemia-reperfusion injury. They noted increased glutathione (GSH), superoxide dismutase (SOD), and catalase (CAT) levels, with a reduction in malondialdehyde (MDA) and thiobarbituric acid reactive substances (TBARS) (see Table 4). These observations underscore a favorable correlation between enzymatic and non-enzymatic antioxidant activity and lipid peroxidation, confirming the beneficial effects of chokeberry ^(43,44). In contrast, Čujić et al. conducted a study where hypertensive rats were administered 50 mg/kg bw/day of black chokeberry extract for 28 days, which led to a decrease in both TBARS and SOD levels. Čujić suggests that the reduced SOD activity may be attributed to the chokeberry compounds' capacity to scavenge superoxide anions, consequently lowering the substrate (superoxide anions) required for the SOD dismutation reaction (see Table 4) ⁽²⁴⁾. In contrast, Rudic et al. supplemented female rats with chokeberry extract at a dose of 0.45 ml/kg b.w. per day for 28 days, observing an increase in GSH and CAT levels, no change in SOD levels, and a decrease in TBARS levels. The elevation in GSH may account for the inhibition of lipid peroxidation and the subsequent decrease in TBARS; however, the reason for the increased CAT without a concurrent change in SOD remains unclear (see Table 4) ⁽³¹⁾. Some researchers propose that an increase in one antioxidant may prompt a compensatory decrease in another due to converse reactions ⁽⁶³⁾.

Liu et al. supplemented pigs with a chokeberry-rich diet for 28 days but observed no changes in SOD, CAT, and T-AOC biomarkers. They attribute this discrepancy to the need for

polyphenols present in black chokeberry to be hydrolyzed by microbes or endogenous enzymes, limiting their bioavailability to monogastric animals (Table 4)⁽⁴²⁾. Additionally, discussing the observed positive effects of black chokeberry following long-term supplementation could provide valuable insights. Dabrowski et al., for example, demonstrated the beneficial effects of long-term administration of black chokeberry extract, both alone and in cadmium poisoning models, in rats. They noted increased SOD activity and TAS values, along with decreased TOS levels, after 10 months of chokeberry extract administration, affirming the antioxidant properties of the extract (Table 4)⁽⁵³⁾.

There is considerably less research on humans compared to animal models. Furthermore, comparing studies involving humans is complicated by the diversity of study groups, which include athletes, healthy individuals, and patients with various conditions. For example, Duchnowicz et al. supplemented patients with hypercholesterolemia with 300 ml/day of chokeberry extract for 2 months, observing a reduction in TBARS levels (see Table 5)⁽¹¹⁾. Broncel et al. administered the same dose and duration of chokeberry extract to patients with metabolic syndrome. They reported reductions in TBARS and CAT levels and increases in GSH-pX and SOD indices after one month of supplementation. The researchers suggested that anthocyanins could serve as direct substrates for peroxidases, leading to the deactivation of hydrogen peroxide and thereby increasing GSH-Px activity. Additionally, they explained that hydrogen peroxide is deactivated in two reactions catalyzed by CAT and GSH-Px, thus, high GSH-Px activity reduces the substrate concentration for CAT, inhibiting CAT activity via negative feedback (see Table 5)⁽⁶⁴⁾. In contrast, Chung et al. used 300 mg/day of chokeberry extract for 8 weeks in healthy subjects. The researchers showed a statistically significant increase in GSH and GPx concentrations and no significant changes in CAT, SOD, and MDA concentrations. The explanation provided by Chung et al. indicates that the glutathione defense system was most sensitive in response to exercise used as a 'factor' to disrupt the prooxidant-antioxidant balance. However, unlike the glutathione defense system, SOD and CAT remained stable in the proposed model. This may indicate that the antioxidant enzyme response is dependent on the 'severity' of oxidative stress (Table 5)⁽⁶⁸⁾. Thus, discrepancies in antioxidant enzyme activity may be, at least partially, attributed to differences in the pathological conditions responsible for oxidation-antioxidation imbalance.

Analyzing studies on athletes, in whom oxidative stress arose as a response to an intense physical exertion, we also observed the effectiveness of chokeberry supplements. Researchers often confirm this by demonstrating a reduction in TBARS concentrations^(65,66) (see Table 5). However, given the recent systematic review that focused on the effects of

chokeberry in a model of exercise ⁽³⁾, we omit further analysis.

In summary, studies conducted on both animal models and human subjects collectively affirm the antioxidant properties of *Aronia melanocarpa*. This is primarily evidenced by alterations in the concentration of enzymes crucial for maintaining the balance between oxidation and antioxidation. However, the biomarkers analyzed do not always exhibit expected behavior. It can be inferred that the impact on antioxidant enzyme levels is contingent upon two factors. Firstly, the severity of oxidative stress, which is influenced by the characteristics of the study population. Secondly, the content of biologically active compounds that directly mitigate oxidative stress, which is related to the dose, type of supplement administered (e.g., juice, extract, fruit), and the duration of supplementation.

Effects of black chokeberry on markers of inflammation

After analyzing the findings from the systematic review, it is evident that the bioactive compounds in black chokeberry exert significant anti-inflammatory effects by modulating cytokine profiles. This modulation involves a complex interplay between various pro-inflammatory and anti-inflammatory mediators within the immune system. In animal models (see Table 4), it has been shown, that these compounds can reduce the levels of pro-inflammatory cytokines such as interleukin-1 beta (IL-1 β) ^(25,40,44,47) and tumor necrosis factor-alpha (TNF- α) ^(25,40,41,44,46–48), act as primary inflammatory stimuli during the cell signaling process.

To elucidate the impact of chokeberry on inflammation, oxidative stress, and their interactions, it is critical to examine the role of adenosine monophosphate-activated protein kinase (AMPK), which modulates the nuclear factor kappa-B (NF- κ B) and nuclear factor erythroid 2-related factor 2 (Nrf2) pathways ^(27,71). Nrf2 is a pivotal regulator of various antioxidants and oversees the activity of antioxidant enzymes, including heme oxygenase-1 (HO-1), catalase (CAT), superoxide dismutase (SOD), and glutathione peroxidase (GPx) ⁽²⁷⁾. According to Zhao et al., black chokeberry influences AMPK activation, leading to the inhibition of the mammalian target of rapamycin (mTOR) activity. This subsequently activates the PI3K/Akt/mTOR pathway through the regulation of Nrf2 nuclear translocation, resulting in enhanced production of antioxidant enzymes ⁽³⁴⁾. However, the direct phosphorylation effect of AMPK on Nrf2 remains to be clarified ⁽⁷²⁾.

NF- κ B is a transcription factor that triggers the production of pro-inflammatory factors ⁽⁴⁴⁾. AMPK activation stimulates factors such as SIRT1, PGC-1 α , p53, and FoxO, which can inhibit NF- κ B signaling, thereby preventing the synthesis of pro-inflammatory

factors⁽⁷¹⁾. Additionally, Wang et al. demonstrated that AMPK inhibition of NF- κ B signaling reduces the expression of various NAD(P)H oxidase subunits, decreasing the production of reactive oxygen species (ROS) and thereby alleviating oxidative stress⁽⁷³⁾. Furthermore, Li et al. indicated that Nrf2 can inhibit NF- κ B signaling, suggesting that Nrf2 activators have anti-inflammatory properties⁽⁷⁴⁾ (Figure 2).

These interactions have been corroborated by other researchers. For instance, Li et al. conducted an experiment in which male mice were administered an extract containing cyanidin-3-arabinoxide, cyanidin-3-glucoside, and cyanidin-3-galactoside at a dosage of 50 mg/g body weight. These anthocyanins are potent antioxidants capable of neutralizing reactive oxygen species (ROS), thereby mitigating oxidative stress, which is frequently associated with chronic inflammation. The authors demonstrated a significant reduction in the levels of IL-1 β , TNF- α , and IL-6, indicating a suppression of the inflammatory response. The study further elucidated that the production of pro-inflammatory cytokines, particularly TNF- α and IL-1 β , is mediated by the transcription factor NF- κ B, which is activated through Toll-like receptor 4 (TLR4) signaling. Activation of TLR4 is positively correlated with inducible nitric oxide synthase (iNOS), thereby linking inflammation and oxidative stress (Table 4)⁽⁴⁴⁾. This is also confirmed by Wang et al. who indicated that it is ROS that activates T lymphocytes, which release inflammatory factors (Table 4)⁽⁴¹⁾. Furthermore, Ohgami et al. also indicate that it is the antioxidant effect of chokeberries that is responsible for inflammatory responses. The authors confirm this with a reduction in NO production, which led to inhibition of NOS and, consequently, a reduction in the inflammatory cytokine TNF- α . In addition, the researchers emphasize that, firstly, the anti-inflammatory effect of chokeberry is dose-dependent. Secondly, the authors point out that the anti-inflammatory mechanism of anthocyanin compounds consists of several factors. Ohgami et al. explain that one of the anti-inflammatory mechanisms of chokeberry is the blocking of COX-2 protein expression. COX-2 is primarily responsible for increased PGE2 production during inflammation, and PGE2 is generally considered a pro-inflammatory agent (Table 4)⁽⁶³⁾ (Figure 2).

Only five studies analyzing biomarkers of inflammation in humans were included in the systematic review. Skarpańska-Stejnborn et al. reported a statistically significant reduction in TNF- α levels following the administration of 150 ml of chokeberry juice daily for eight weeks to elite rowers. The authors suggest that anthocyanins in chokeberry juice may attenuate the activity of major inflammatory enzymes and prevent the adhesion of leukocytes to vascular endothelial cells by inactivating TNF- α (Table 5),⁽⁶⁾

In contrast, Xie et al. observed no significant changes in inflammatory biomarkers when supplementing 500 mg/day of chokeberry extract for 12 weeks among former smokers. The researchers propose that the anti-inflammatory effects of polyphenols from chokeberry may be more pronounced in populations suffering from chronic inflammation, rather than in relatively healthy individuals (Table 4). This suggests that the efficacy of chokeberry-derived polyphenols might be contingent upon the baseline inflammatory status of the subjects (Table 5), ⁽⁶⁷⁾.

We hypothesize that the administration of black chokeberry exerts a notable impact on inflammation reduction, intricately linked to the mitigation of reactive oxygen species (ROS) and subsequent oxidative stress. However, this reduction appears to be observed in increased and chronic inflammation. A clear discrepancy emerges between studies focusing on inflammation reduction and those targeting oxidative stress, with approximately 70% fewer studies analyzing inflammation biomarkers. This underscores the imperative for future experiments to delve deeper into elucidating the trajectory of alterations and the intricacies involved in mitigating the inflammatory process after chokeberry use. Such endeavors are crucial for comprehensively understanding the mechanisms underlying the anti-inflammatory properties of chokeberry and optimizing its therapeutic potential in combating inflammatory conditions.

Effect of black chokeberry on intestinal parameters

Diversity and richness are pivotal parameters characterizing the human gut microbiota, with implications extending to various health outcomes ⁽⁴⁵⁾. Diminished gene diversity and richness within the intestinal microbiome are frequently observed in individuals afflicted with diverse disorders, such as obesity ⁽⁷⁵⁾, type-2 diabetes mellitus ⁽⁷⁵⁾, psychiatric disorders ⁽⁷⁶⁾, Crohn's disease ⁽⁷⁷⁾, or even in infants delivered by cesarean section ⁽⁷⁸⁾. Clinical interventions (e.g., antibiotics, drug use) and environmental factors (e.g., smoking, diet, and physical activity) also affect microbial diversity ⁽⁷⁹⁾.

Supplementation with *Aronia melanocarpa* has been explored for its potential impact on gut health; however, no effect on alpha and beta diversity has been observed in human studies ^(12,69,70). In animal research, results were inconclusive. In three studies, parameters remained at the same level ^(30,40,51), and in three, they increased ^(35,38,43). However, the *Firmicutes/Bacteroides* ratio tended to lower in animal models ^(30,51). It is a widely accepted marker that has an essential influence on maintaining normal intestinal homeostasis. An

increased or decreased F/B ratio is regarded as dysbiosis, whereby the former is usually observed concerning obesity and the latter to inflammatory bowel disease⁽⁸⁰⁾. Both studies were carried out on high-fat diet models suggesting a potential trend in reducing the *Firmicutes/Bacteroidetes* (F/B) ratio in obesity following *Aronia melanocarpa* supplementation^(30,51). Moreover, increases in *Bacteroides* and *Bacteroidetes* have been consistently noted across studies^(12,30,40,43,51,70). Notably, *Bacteroides* play a crucial role in supplying nutrients to other microbial residents of the gut, thereby contributing to the overall balance and functioning of the gut microbiota. Furthermore, they serve as a protective barrier against pathogens, helping to maintain intestinal homeostasis and prevent infections. This highlights the potential importance of increasing *Bacteroides* abundance through *Aronia* supplementation to promote gut health and mitigate the risk of various gastrointestinal disorders⁽⁸¹⁾.

We also noticed a rise in *Verrucomicrobia* and *Akkermansia muciphila*^(30,51), which are connected to gut health⁽⁸²⁾ and are even proposed as a next-generation probiotic⁽⁸³⁾. Furthermore, levels of *Prevotella* also increased^(30,40,51). The Western lifestyle is causal in the loss of *Prevotella* diversity, and aronia could reverse this pathway. An increase in *Romboutsia* was also observed^(30,40,51), the bacterium is negatively correlated with body weight, insulin, and fasting glucose. In the end, the abundance of pathogens in the gut decreased after *Aronia* supplementation: *Proteobacteria*, the microbial signature of dysbiosis⁽⁸⁴⁾, was decreased (44); *Escherichia-Shigella* associated not only with dysbiosis but also with inflammation was also decreased⁽⁴⁰⁾, *Haemophilus parainfluenzae*, which may cause infections of soft tissue, central nervous system (CNS), and endocarditis⁽⁸⁵⁾ followed the same pattern⁽¹²⁾. To summarize, supplementation with *Aronia melanocarpa* may positively affect gut health, especially by reducing potential pathogens, and increasing the abundance of bacteria positively correlated to gut health, such as *Akkermansia* and *Bacteroidetes*. In our review, only one study on gut permeability was conducted on growing pigs. *Aronia* significantly increased the jejunal gene expression of tight junction proteins, such as occluding, claudin, and zonulin⁽⁴⁰⁾, thus improving gut barrier tightness. Another study carried out on a rat model of obesity confirmed *Aronia*'s positive impact on gut tightness, but it was not approved for the review process due to the lack of full text⁽⁸⁶⁾. Preliminary animal studies may suggest the possibility of chokeberry influencing the tightness of the intestinal barrier.

The compounds found in black chokeberry play a pivotal role in maintaining the overall balance within the system. This is a crucial consideration given the tendency for disturbances in organismal homeostasis to accompany disease processes and various disorders. Chokeberry not only reduces oxidative stress and modulates the inflammatory response but also influences the composition of the intestinal microbiome through the growth of bacteria, which are positively correlated with health. This underscores the potential of natural supplements, like chokeberry in restoring systemic equilibrium, as evidenced by numerous studies highlighting their efficacy across a spectrum of physiological processes. However, it is imperative to acknowledge the significant divergence between findings in human and animal studies. While existing research underscores the potential benefits of chokeberry supplementation, particularly in prophylactic contexts aimed at preserving organism harmony and homeostasis, further investigation is warranted to fully elucidate its mechanisms and optimize its application. Moreover, the substantial gap between studies focusing on oxidative stress, inflammation, and intestinal parameters underscores the necessity for additional research to comprehensively understand the effects of chokeberry on inflammation and microbiota alterations. Additionally, the observation of fewer studies involving women compared to men highlights an area requiring considerable attention and clarification. Addressing these research gaps would be pivotal in further understanding the potential benefits and optimal applications of black chokeberry supplementation for promoting overall health and mitigating disease risk across diverse populations.

Limitations:

The primary limitation of this review is the considerable heterogeneity in the methodologies of the included studies. Variations in supplementation duration, type of supplement (e.g., extract, juice, fruit), dosage, and sample sizes among the studies introduce substantial challenges in result comparison. Additionally, the diversity of study populations and the significant discrepancies between human and animal model studies further complicate the synthesis of findings. A notable concern is the predominance of studies from Eastern countries, which raises questions about the generalizability of the results to Western populations. These factors necessitate a cautious interpretation of the review's conclusions. Furthermore, despite employing the PRISMA protocol for article selection, there remains a possibility that some relevant manuscripts were inadvertently omitted. Another critical limitation is the presence of significant sources of bias in many of the studies analyzed. This is particularly noticeably true for studies on animal models. This may indicate that scientists are still not very familiar with this tool.

Acknowledgments:

Competing interests

The authors declare no conflict of interest.

Financial support: “This research received no specific grant from any funding agency, commercial or not-for-profit sectors.”

Statement of authors’ contributions to manuscript: SK and HDz study design, data collection, and writing – original draft preparation. AK, MP, HDz, SK data analysis; ASS, JOK writing – review and editing. All authors have read and approved the final manuscript.

Availability of data and materials

Data are available from the corresponding author upon reasonable request.

References

1. Jurendić T & Ščetar M (2021) Aronia melanocarpa Products and By-Products for Health and Nutrition: A Review. *Antioxidants* **10**. doi:10.3390/antiox10071052.
2. Kasprzak-Drozd K, Oniszczyk T, Soja J *et al.* (2021) The Efficacy of Black Chokeberry Fruits against Cardiovascular Diseases. *Int J Mol Sci* **22**. doi:10.3390/ijms22126541.
3. Zare R, Kimble R, Redha AA *et al.* (2023) How can chokeberry (Aronia) (poly)phenol-rich supplementation help athletes? A systematic review of human clinical trials. *Food Funct* **14**, 5478–5491.
4. Bowtell J & Kelly V (2019) Fruit-Derived Polyphenol Supplementation for Athlete Recovery and Performance. *Sports Med* **49**, 3–23.
5. Naruszewicz M, Laniewska I, Millo B *et al.* (2007) Combination therapy of statin with flavonoids rich extract from chokeberry fruits enhanced reduction in cardiovascular risk markers in patients after myocardial infraction (MI). *Atherosclerosis* **194**, e179-184.
6. Skarpańska-Stejnborn A, Basta P, Sadowska J *et al.* (2014) Effect of supplementation with chokeberry juice on the inflammatory status and markers of iron metabolism in rowers. *J Int Soc Sports Nutrients* **11**, 48.

7. Stankiewicz B, Cieślicka M, Kujawski S *et al.* (2021) Effects of antioxidant supplementation on oxidative stress balance in young footballers- a randomized double-blind trial. *J Int Soc Sports Nutrients* **18**, 44.
8. Jurikova T, Mlcek J, Skrovankova S *et al.* (2017) Fruits of Black Chokeberry *Aronia melanocarpa* in the Prevention of Chronic Diseases. *Molecules* **22**, 944.
9. Bell DR & Gochenaur K (2006) Direct vasoactive and vasoprotective properties of anthocyanin-rich extracts. *J Appl Physiol (1985)* **100**, 1164–1170.
10. Milutinovic M, Velickovic Radovanovic R *et al.* (2019) Chokeberry juice supplementation in type 2 diabetic patients - impact on health status. *J Appl Biomed* **17**, 218–224.
11. Duchnowicz P, Nowicka A, Koter-Michalak M *et al.* (2012) In vivo influence of extract from *Aronia melanocarpa* on the erythrocyte membranes in patients with hypercholesterolemia. *Med Sci Monit* **18**, CR569–CR574.
12. Le Sayec M, Xu Y, Laiola M *et al.* (2022) The effects of *Aronia* berry (poly)phenol supplementation on arterial function and the gut microbiome in middle aged men and women: Results from a randomized controlled trial. *Clin Nutr* **41**, 2549–2561.
13. Stankiewicz B, Cieślicka M, Mieszkowski J *et al.* (2023) Effect of Supplementation with Black Chokeberry (*Aronia melanocarpa*) Extract on Inflammatory Status and Selected Markers of Iron Metabolism in Young Football Players: A Randomized Double-Blind Trial. *Nutrients* **15**, 975.
14. Hills RD, Pontefract BA, Mishcon HR *et al.* (2019) Gut Microbiome: Profound Implications for Diet and Disease. *Nutrients* **11**, 1613.
15. Kennedy DO (2014) Polyphenols and the human brain: plant “secondary metabolite” ecologic roles and endogenous signaling functions drive benefits. *Adv Nutr* **5**, 515–533.
16. M G, M E, F B-D, A C, A N, Pg B *et al.* (2021) Continuous flow insufflation of oxygen for cardiac arrest: Systematic review of human and animal model studies. *Resuscitation* **162**. doi:10.1016/j.resuscitation.2021.03.009.

17. Higgins JPT, Altman DG, Gøtzsche PC *et al.* (2011) The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. *BMJ* **343**, d5928.
18. Hooijmans CR, Rovers MM, de Vries RB *et al.* (2014) SYRCLE's risk of bias tool for animal studies. *BMC Med Res Methodol* **14**, 43.
19. Valcheva-Kuzmanova S, Marazova K, Krasnaliev *et al.* (2005) Effect of Aronia melanocarpa fruit juice on indomethacin-induced gastric mucosal damage and oxidative stress in rats. *Exp Toxicol Pathol* **56**, 385–392.
20. Kujawska M, Ignatowicz E, Ewertowska M *et al.* (2011) Protective effect of chokeberry on chemical-induced oxidative stress in rat. *Hum Exp Toxicol* **30**, 199–208.
21. Ma C, Lyu M, Deng C *et al.* (2022) Cyanidin-3-galactoside ameliorates silica-induced pulmonary fibrosis by inhibiting fibroblast differentiation via Nrf2/p38/Akt/NOX4. *J Funct Foods* **92**, 105034.
22. Piotrowska-Kempisty H, Nowicki M, Jodynis-Liebert J *et al.* (2020) Assessment of Hepatoprotective Effect of Chokeberry Juice in Rats Treated Chronically with Carbon Tetrachloride. *Molecules* **25**, 1268.
23. Ciocoiu M, Badescu L, Miron A *et al.* (2013) The involvement of a polyphenol-rich extract of black chokeberry in oxidative stress on experimental arterial hypertension. *Evid Based Complement Alternat Med* **2013**, 912769.
24. Čujić N, Savikin K, Miloradovic Z *et al.* (2018) Characterization of dried chokeberry fruit extract and its chronic effects on blood pressure and oxidative stress in spontaneously hypertensive rats. *J Funct Foods* **44**, 330–339.
25. Jiao X, Shen Y, Deng H *et al.* (2021) Cyanidin-3-O-galactoside from Aronia melanocarpa attenuates high-fat diet-induced obesity and inflammation via AMPK, STAT3, and NF-κB p65 signaling pathways in Sprague-Dawley rats. *J Funct Foods* **85**, 104616.
26. Kim B, Ku CS, Pham TX *et al.* (2013) Aronia melanocarpa (chokeberry) polyphenol-rich extract improves antioxidant function and reduces total plasma cholesterol in apolipoprotein E knockout mice. *Nutr Res* **33**, 406–413.

27. Jeong H, Liu Y, & Kim H-S (2017) Dried plum and chokeberry ameliorate d-galactose-induced aging in mice by regulation of PI3k/Akt-mediated Nrf2 and Nf-kB pathways. *Exp Gerontol* **95**, 16–25.
28. Song E-K, Park H, & Kim H-S (2019) Additive effect of walnut and chokeberry on regulation of antioxidant enzyme gene expression and attenuation of lipid peroxidation in d-galactose-induced aging-mouse model. *Nutr Res* **70**, 60–69.
29. Lipińska P, Atanasov AG, Palka M *et al.* (2017) Chokeberry Pomace as a Determinant of Antioxidant Parameters Assayed in Blood and Liver Tissue of Polish Merino and Wrzosówka Lambs. *Molecules* **22**, 1461.
30. Zhu Y, Zhang J, Wei Y *et al.* (2020) The polyphenol-rich extract from chokeberry (*Aronia melanocarpa* L.) modulates gut microbiota and improves lipid metabolism in diet-induced obese rats. *Nutr Metab (Lond)* **17**, 54.
31. Rudic J, Jakovljevic V, Jovic N *et al.* (2022) Antioxidative Effects of Standardized *Aronia melanocarpa* Extract on Reproductive and Metabolic Disturbances in a Rat Model of Polycystic Ovary Syndrome. *Antioxidants (Basel)* **11**, 1099.
32. Pavlova V, Sainova I, Alexieva B *et al.* (2014) Antioxidant effect of *Aronia melanocarpa* extract after doxorubicin treatment. *Bulg J Agric Sci* **20**, 188–192.
33. Yu S-Y, Kim M-B, Park Y-K *et al.* (2021) Anthocyanin-Rich *Aronia* Berry Extract Mitigates High-Fat and High-Sucrose Diet-Induced Adipose Tissue Inflammation by Inhibiting Nuclear Factor- κ B Activation. *J Med Food* **24**, 586–594.
34. Zhao Y, Liu X, Zheng Y *et al.* (2021) *Aronia melanocarpa* polysaccharide ameliorates inflammation and aging in mice by modulating the AMPK/SIRT1/NF- κ B signaling pathway and gut microbiota. *Sci Rep* **11**, 20558.
35. Liu X, Martin DA, Valdez JC *et al.* (2021) *Aronia* berry polyphenols have matrix-dependent effects on the gut microbiota. *Food Chem* **359**, 129831.
36. Xing Y, Liang S, Zhang L *et al.* (2023) Combination of *Lactobacillus fermentum* NS9 and *aronia* anthocyanidin extract alleviates sodium iodate-induced retina degeneration. *Sci Rep* **13**, 8380.

37. Liu X, Zhang X, Gao Y *et al.* (2023) Cyanidin-3-galactoside from *Aronia melanocarpa* ameliorates PM10-induced pulmonary inflammation by promoting PINK1/Parkin signaling pathway-mediated alveolar macrophage mitophagy. *eFood* **4**, e119.
38. Wilson SMG, Peach JT, Fausset H *et al.* (2023) Metabolic impact of polyphenol-rich aronia fruit juice mediated by inflammation status of gut microbiome donors in humanized mouse model. *Front Nutr* **10**, 1244692.
39. Doma AO, Cristina RT, Dumitrescu E *et al.* (2023) The antioxidant effect of *Aronia melanocarpa* extract in rats oxidative stress induced by cisplatin administration. *J Trace Elem Med Biol* **79**, 127205.
40. Ren Z, Fang H, Zhang J, Wang R *et al.* (2022) Dietary *Aronia melanocarpa* Pomace Supplementation Enhances the Expression of ZO-1 and Occludin and Promotes Intestinal Development in Pigs. *Front Vet Sci* **9**, 904667.
41. Wang Z, Liu Y, Zhao X *et al.* (2020) *Aronia melanocarpa* Prevents Alcohol-Induced Chronic Liver Injury via Regulation of Nrf2 Signaling in C57BL/6 Mice. *Oxid Med Cell Longev* **2020**, 4054520.
42. Liu XZ, Ju Y, Bao N *et al.* (2021) Effects of polyphenol-rich *Aronia melanocarpa* pomace feeding on growth performance, biochemical profile, and meat quality in pigs at weaned and finishing stages. *Livest Sci* **252**, 104674.
43. Zhao Y, Liu X, Ding C *et al.* (2022) *Aronia melanocarpa* polysaccharide ameliorates liver fibrosis through TGF- β 1-mediated the activation of PI3K/AKT pathway and modulating gut microbiota. *J Pharmacol Sci* **150**, 289–300.
44. Li L, Li J, Xu H *et al.* (2021) The Protective Effect of Anthocyanins Extracted from *Aronia Melanocarpa* Berry in Renal Ischemia-Reperfusion Injury in Mice. *Mediators of Inflammation* **2021**, e7372893.
45. Wei J, Zhang G, Zhang X *et al.* (2017) Anthocyanins from Black Chokeberry (*Aroniamelanocarpa* Elliot) Delayed Aging-Related Degenerative Changes of Brain. *J Agric Food Chem* **65**, 5973–5984.

46. Yang J, Gao J, Yu W et al. (2020) The effects and mechanism of Aronia melanocarpa Elliot anthocyanins on hepatic fibrosis. *J Funct Foods* **68**, 103897.
47. Wang Z, Wang X, Yan H et al. (2019) Aronia melanocarpa ameliorates gout and hyperuricemia in animal models. *Food Agric Immunol* **30**, 47–59.
48. Valcheva-Kuzmanova S, Stavreva G, Dancheva V et al. (2014) Effect of Aronia melanocarpa fruit juice on amiodarone-induced pneumotoxicity in rats. *Pharmacogn Mag* **10**, 132–140.
49. Frankiewicz-Józko A & Faff J (2003) Effect of anthocyanins from aronia melanocarpa on the exercise-induced oxidative stress in rat tissues. *Biology of Sport* **20**, 15–23.
50. Onopiuk BM, Dąbrowska ZN, Rogalska et al. (2021) The Beneficial Impact of the Black Chokeberry Extract against the Oxidative Stress in the Sublingual Salivary Gland of Rats Intoxicated with Cadmium. *Oxid Med Cell Longev* **2021**, e6622245.
51. Zhu Y, Wei Y-L, Karras I et al. (2022) Modulation of the gut microbiota and lipidomic profiles by black chokeberry (Aronia melanocarpa L.) polyphenols via the glycerophospholipid metabolism signaling pathway. *Front Nutr* **9**, 913729.
52. Dąbrowska Z, Dąbrowska E, Onopiuk B et al. (2019) The Protective Impact of Black Chokeberry Fruit Extract (Aronia melanocarpa L.) on the Oxidoreductive System of the Parotid Gland of Rats Exposed to Cadmium. *Oxid Med Cell Longev* **2019**, 3403264.
53. Dąbrowski A, Onopiuk BM, Car H et al. (2020) Beneficial Impact of an Extract from the Berries of Aronia melanocarpa L. on the Oxidative-Reductive Status of the Submandibular Gland of Rats Exposed to Cadmium. *Antioxidants* **9**, 185.
54. Wei J, Zhang C, Tang X et al. (2023) Synergistic protection of combined Aronia melanocarpa Elliot anthocyanins with Aloe Polysaccharides inhibits alcoholic liver injury in mice. *Food Biosci* **55**, 102938.
55. Mężyńska M, Brzóska MM, Rogalska J et al. (2019) Extract from Aronia melanocarpa L. Berries Protects Against Cadmium-induced Lipid Peroxidation and Oxidative Damage to Proteins and DNA in the Liver: A Study using a Rat Model of Environmental Human Exposure to this Xenobiotic. *Nutrients* **11**, 758.

56. Jing B, Xiao H, Yin H *et al.* (2022) Feed Supplemented with Aronia melanocarpa (AM) Relieves the Oxidative Stress Caused by Ovulation in Peak Laying Hens and Increases the Content of Yolk Precursors. *Animals (Basel)* **12**, 3574.
57. Brzóška M, Tomczyk M, Rogalska J *et al.* (2015) Protective impact of extract from Aronia melanocarpa berries against low-level exposure to cadmium-induced lipid peroxidation in the bone tissue: a study in a rat model. *Planta Med* **81**. doi:10.1055/s-0035-1565404.
58. Mężyńska M, Brzóška MM, Rogalska J *et al.* (2018) Extract from Aronia melanocarpa L. Berries Prevents Cadmium-Induced Oxidative Stress in the Liver: A Study in A Rat Model of Low-Level and Moderate Lifetime Human Exposure to this Toxic Metal. *Nutrients* **11**, 21.
59. Wang T, Cong Y, Qu H *et al.* (2023) Protective effect of dietary *Aronia melanocarpa* extract against ammonia stress in juvenile *Eriocheir sinensis*. *Aquac Res* **31**, 101633.
60. Smereczański NM, Brzóška MM, Rogalska J, & Hutsch T (2023) The Protective Potential of Aronia melanocarpa L. Berry Extract against Cadmium-Induced Kidney Damage: A Study in an Animal Model of Human Environmental Exposure to This Toxic Element. *Int J Mol Sci* **24**, 11647.
61. Ruczaj A, Brzóška MM, & Rogalska J (2024) The Protective Impact of Aronia melanocarpa L. Berries Extract against Prooxidative Cadmium Action in the Brain—A Study in an In Vivo Model of Current Environmental Human Exposure to This Harmful Element. *Nutrients* **16**, 502.
62. Gajic D, Saksida T, Koprivica I *et al.* (2020) Chokeberry (*Aronia melanocarpa*) fruit extract modulates immune response in vivo and in vitro. *J Func Foods* **66**, 103836.
63. Ohgami K, Ilieva I, Shiratori K *et al.* (2005) Anti-inflammatory effects of aronia extract on rat endotoxin-induced uveitis. *Invest Ophthalmol Vis Sci* **46**, 275–281.
64. Broncel M, Kozirog M, Duchnowicz P *et al.* (2009) Aronia melanocarpa extract reduces blood pressure, serum endothelin, lipid, and oxidative stress marker levels in patients with metabolic syndrome. *Med Sci Monit* **16**, CR28–CR34.

65. Pilaczynska-Szczesniak L, Skarpanska-Steinborn A, Deskur E *et al.* (2005) The influence of chokeberry juice supplementation on the reduction of oxidative stress resulting from an incremental rowing ergometer exercise. *Int J Sport Nutr Exerc Metab* **15**, 48–58.
66. Petrovic S, Arsic A, Glibetic M *et al.* (2016) The effects of polyphenol-rich chokeberry juice on fatty acid profiles and lipid peroxidation of active handball players: results from a randomized, double-blind, placebo-controlled study. *Can J Physiol Pharmacol* **94**, 1058–1063.
67. Xie L, Vance T, Kim B *et al.* (2017) Aronia berry polyphenol consumption reduces plasma total and low-density lipoprotein cholesterol in former smokers without lowering biomarkers of inflammation and oxidative stress: a randomized controlled trial. *Nutr Res* **37**, 67–77.
68. Chung J-W, Kim J-E, Nam Y *et al.* Eight-week supplementation of Aronia berry extract promoted the glutathione defence system against acute aerobic exercise-induced oxidative load immediately and 30 min post-exercise in healthy adults: a double-blind, randomised controlled trial. *J Hum Nutr Diet* **n/a**. doi:10.1111/jhn.13150.
69. Lackner S, Mahnert A, Moissl-Eichinger C *et al.* (2024) Interindividual differences in aronia juice tolerability linked to gut microbiome and metabolome changes-secondary analysis of a randomized placebo-controlled parallel intervention trial. *Microbiome* **12**, 49.
70. Istas G, Wood E, Le Sayec M, Rawlings C *et al.* (2019) Effects of aronia berry (poly)phenols on vascular function and gut microbiota: a double-blind randomized controlled trial in adult men. *Am J Clin Nutr* **110**, 316–329.
71. Salminen A, Hyttinen JMT, & Kaarniranta K (2011) AMP-activated protein kinase inhibits NF- κ B signaling and inflammation: impact on healthspan and lifespan. *J Mol Med (Berl)* **89**, 667–676.
72. Petsouki E, Cabrera SNS, & Heiss EH (2022) AMPK and NRF2: Interactive players in the same team for cellular homeostasis? *Free Radic Biol Med* **190**, 75–93.

73. Wang S, Zhang M, Liang B *et al.* (2010) AMPK α 2 deletion causes aberrant expression and activation of NAD(P)H oxidase and consequent endothelial dysfunction in vivo: role of 26S proteasomes. *Circ Res* **106**, 1117–1128.
74. Li R, Jia Z, & Zhu H (2019) Regulation of Nrf2 Signaling. *React Oxyg Species (Apex)* **8**, 312–322.
75. Cheng Z, Zhang L, Yang L, & Chu H (2022) The critical role of gut microbiota in obesity. *Front Endocrinol (Lausanne)* **13**, 1025706.
76. Nikolova VL, Smith MRB, Hall LJ *et al.* (2021) Perturbations in Gut Microbiota Composition in Psychiatric Disorders: A Review and Meta-analysis. *JAMA Psychiatry* **78**, 1343–1354.
77. Imhann F, Vich Vila A, Bonder MJ *et al.* (2018) Interplay of host genetics and gut microbiota underlying the onset and clinical presentation of inflammatory bowel disease. *Gut* **67**, 108–119.
78. Jakobsson HE, Abrahamsson TR, Jenmalm MC *et al.* (2014) Decreased gut microbiota diversity, delayed Bacteroidetes colonisation and reduced Th1 responses in infants delivered by caesarean section. *Gut* **63**, 559–566.
79. Wei Y, Li Y, Yan L, Sun C *et al.* (2020) Alterations of gut microbiome in autoimmune hepatitis. *Gut* **69**, 569–577.
80. Stojanov S, Berlec A, & Štrukelj B (2020) The Influence of Probiotics on the Firmicutes/Bacteroidetes Ratio in the Treatment of Obesity and Inflammatory Bowel disease. *Microorganisms* **8**. doi:10.3390/microorganisms8111715.
81. Zafar H & Saier MHJ (2021) Gut Bacteroides species in health and disease. *Gut Microbes* **13**, 1–20.
82. Derrien M, Belzer C, & de Vos WM (2017) Akkermansia muciniphila and its role in regulating host functions. *Microb Pathog* **106**, 171–181.
83. Zhai Q, Feng S, Arjan N, & Chen W (2019) A next generation probiotic, Akkermansia muciniphila. *Crit Rev Food Sci Nutr* **59**, 3227–3236.

84. Shin N-R, Whon TW, & Bae J-W (2015) Proteobacteria: microbial signature of dysbiosis in gut microbiota. *Trends Biotechnol* **33**, 496–503.
85. Onafowokan OO, Mateo R, & Bonatti HJR (2021) A Series of Haemophilus parainfluenzae Surgical Infections and Review of the Literature. *Surg Infect (Larchmt)* **22**, 940–947.
86. Zhu Y, Cai P-J, Dai H-C *et al.* (2023) Black chokeberry (*Aronia melanocarpa* L.) polyphenols attenuate obesity-induced colonic inflammation by regulating gut microbiota and the TLR4/NF- κ B signaling pathway in high fat diet-fed rats. *Food Funct* **14**, 10014–10030.
87. OCEBM Levels of Evidence. <https://www.cebm.ox.ac.uk/resources/levels-of-evidence/ocebm-levels-of-evidence> (accessed March 2024).

Table 1. The Oxford 2011 Levels of Evidence ⁽⁸⁷⁾

Evidence Level (Treatment Benefits)
Level 1—Systematic review of randomized trials or n-of-1 trials
Level 2—Randomized trial or observational study with dramatic effect
Level 3—Non-randomized controlled cohort/follow-up study
Level 4—Case series, case-control study, or historically controlled study
Level 5—Mechanism-based reasoning




Figure 1. PRISMA flow diagram illustrating the search and selection of studies.







Figure 2. Effects of AMPK pathway activation on NF-κB and Nrf2 pathways. The color of the black arrow indicates influence. The color of the red arrow indicates inhibition, and the color of the green arrow indicates activation.

Table 2. Cochrane Collaboration Risk-of-Bias Tool. Symbols used: +: low risk; ?: unclear risk; -: high risk.

	Randomization process	Deviation from the intended intervention	Measurement of the outcome	Selection of the reported results	Overall
Duchnowicz (2012)	?	-	-	+	+
Broncel (2010)	+	+	-	+	?
Stankiewicz (2021)	+	+	-	+	+
Petrovic (2016)	+	+	+	+	+
Skarpańska-Stejnborn (2014)	+	+	+	+	+
Xie (2016)	+	-	+	+	+
Pilaczyńska-Szcześniak (2005)	+	-	+	+	+
Istas (2019)	+	+	+	+	+
Le Sayec (2022)	+	+	+	+	+
Chung (2023)	?	?	?	+	+
Lacker (2024)	+	?	+	+	+
Stankiewicz (2023)	+	+	+	+	+

Table 3 SYRCLE's risk of bias tool for animal studies. (1) Sequence generation; (2) Baseline characteristics; (3) Allocation concealment; (4) Random housing; (5) Blinding of experimentalists; (6) Random for outcome assessment; (7) Blinding of outcome assessors; (8) Incomplete outcome data; (9) Selective outcome reporting; (10) Other biases. Symbols used: : low risk; : unclear risk; : high risk.

	1	2	3	4	5	6	7	8	9	10
Zhao (2022)	+	+	?	?	?	?	?	?	?	?
X Liu (2021)	+	?	?	?	?	?	?	?	?	+
Zhu (2020)	+	+	+	?	?	?	?	+	?	?
Rudic (2022)	?	?	?	?	?	?	?	?	?	?
Li (2021)	+	?	?	?	+	?	+	?	?	?
Kujawska (2010)	+	?	?	?	?	?	?	?	?	?
Wei (2017)	+	+	?	?	?	+	?	?	+	?
Ma (2022)	+	+	+	?	?	?	?	?	?	?
Yang (2020)	+	+	+	?	?	?	?	?	?	?
Piotrowska–Kempisty (2020)	+	+	?	?	+	?	?	?	?	?
Dąbrowski (2020)	+	+	+	?	?	?	?	+	?	?
Wang (2020)	+	?	?	?	?	?	?	?	?	?
Ciocioiu (2013)	-	+	?	?	?	?	?	?	?	?
Mężyńska (2019)	+	+	+	?	?	?	?	+	?	?
Wang (2019)	+	+	?	?	?	?	?	?	?	?
Cujića (2018)	+	+	?	?	?	?	?	+	?	?
Pavlova (2024)	+	+	?	?	?	?	?	?	?	?
Jiao (2021)	+	?	?	?	?	?	?	+	?	?
Jing (2022)	+	+	+	+	?	+	?	+	?	?
Valcheva-Kuzmanowa (2014)	-	+	?	?	?	?	?	?	?	?

Liu (2021)	-	+	?	?	?	?	?	?	+	?	?
Yu (2021)	+	?	?	?	?	?	?	?	?	?	?
Ren (2022)	+	+	-	?	?	?	?	?	+	?	?
Kim (2013)	+	?	?	?	?	?	?	?	?	?	?
Jeong (2017)	+	+	?	?	?	?	?	?	?	?	?
Ohgami (2005)	-	+	?	?	?	?	?	?	?	?	?
Song (2018)	+	+	?	?	?	?	?	?	?	?	?
Zhao (2021)	+	+	?	?	?	?	?	?	?	?	?
Zhu (2022)	+	+	?	?	?	?	?	?	?	?	?
Brzóška (2016)	+	+	?	?	?	?	?	?	?	?	?
Faff and Frankiewicz-Józko (2003)	+	+	?	?	?	?	?	?	?	?	?
Lipińska (2017)	+	?	?	?	?	?	?	?	?	?	?
Gajic (2020)	-	?	?	?	?	?	?	?	?	?	?
Onopiuk (2021)	+	+	?	?	?	?	?	?	+	?	?
Valcheva-Kuzmanowa (2005)	+	?	?	?	?	?	?	?	?	?	?
Mężyńska (2018)	+	+	+	?	?	?	?	?	+	?	?
Dąbrowska (2019)	+	+	+	?	?	?	?	?	+	?	?
Xing (2023)	+	+	+	?	?	?	?	?	?	?	?
Liu (2023)	+	+	?	?	?	?	?	?	?	?	?
Wei (2023)	+	+	?	?	?	?	?	?	?	?	?
Wang (2023)	+	+	+	?	?	+	?	?	?	?	?
Smereczański (2023)	+	?	?	?	?	?	?	?	?	?	?
Ruczaj (2024)	+	+	?	?	?	?	?	?	?	?	?
Wilson (2023)	-	?	?	?	?	?	?	?	?	?	?
Doma (2023)	+	+	?	?	?	?	?	?	?	?	?

Table 4. Summary of studies on the effects of chokeberry on inflammation, oxidative stress, and intestinal parameters - an animal model.

Author	Group	Supplement	Dose	Duration of supplementation	Markers of inflammation	Markers of oxidative stress	Changes in gut microbiota
Zhao et al. (2022) (43)	Male ICR mice (4-6 weeks old), N=50, Model group (thioacetamide TAA-induced liver fibrosis), n=10 Aronia (AMP-L), n=10 Aronia (AMP-H), n=10	Chokeberry extract	200 or 400 mg/kg b.w./day	4 weeks		↑ GSH, ↑ SOD, ↓ MDA.	↑ Shannon index, ↑ Simpson index, ↑ PCoA, ↑ The ratio of <i>Bacteroidetes</i> to <i>Proteobacteria</i> .
X Liu et al. (2021) (35)	Male mice (10 weeks old), N=24, Control group, n=6 Aronia berry (AB), n=6 Aronia extract (AE), n=6	Aronia berry and aronia extract	Aronia berry (AB)= 6300 mg/ kg b.w./day	One week			Whole groups: ↑ Shannon index, ↑ PCoA, Aronia berry-supplemented diet: ↑ <i>Erysipelotrichia</i> (marker of diet) ↓ <i>Bacilli</i> , Aronia extract- supplemented diet: <i>Proteobacteria</i> and <i>Deltaproteobacteria</i> (marker of diet)
Zhu et al. (2020) (30)	Male rats (aged 6 weeks) N=38, HF group (high fat diet) n=8 Aronia (continually fed with HFD +AM) n=10	Chokeberry extract	1000 mg/kg b.w./day	40 days			↔ ACE, ↔ Chao1 index, ↔ Shannon index, ← Simpson index, ≠ PCoA ↓ F/B ratio, ↑ <i>Bacteroidetes</i> , ↓ <i>Firmicutes</i> , ↑ <i>Verumicrobia</i> , ↑ <i>Bacteroides</i> , ↑ <i>Romboutsia</i> , ↑ <i>Prevotella</i> , ↑ <i>Akkermansia</i> , ↑ <i>Marvinbryantia</i> , ↑ <i>Anaerofilum</i> , ↓ <i>Clostridium</i> , ↓ <i>Ruminococcaceae_UCG- 013</i> , ↓ <i>Ruminococcaceae_NK4A214_group</i> , ↓ <i>Roseburia</i> , ↓ <i>Desulfovibrio</i> , ↓ <i>Ruminiclostridium_6</i> , ↓ <i>Eubacterium_coprostanoligenes_group</i> .

							Group markers: <i>Bacteroides, Prevotella, and Ruminococcus_1</i>
Rudic et al. (2022) ⁽³¹⁾	Model adult female rats with PCOS, N=30 Model group (P), n=6 Aronia group (P+A), n=6	Standardized Aronia melanocarpa extract	0.45 mL/kg b.w./day	28 days		↓ O ₂ , ↓ H ₂ O ₂ , ↓ TBARS, ↔ nitrites, ↔ SOD, ↑ GSH, ↑ CAT.	
Li et al. (2021) ⁽⁴⁴⁾	Male mice (10-12 weeks old), N=52, n=13 AC (anthocyanin mixture), n=13 C-3-A (cyanidin-3 Arabinoside), n=13 C-3-GA (cyaniding-3-galactoside), n=13 C-3-GL (cyanidin-3-glucodise), n=13	Anthocyanin mixture	50 mg/g b. w./twice daily corresponding to 25 ml/g b.w./ twice daily	14 days	Before the renal IR injury: ↔ IL-1β, ↔ IL-6, ↔ TNF-α, ↔ MCP-1 After renal IR injury: ↓ IL-1β, ↓ TNF-α, ↓ MCP-1, ↓ IL-6	↑ SOD, ↑ CAT, ↑ GSH, ↓ MDA, ↓ TBARS.	
Kujawska et al. (2010) ⁽²⁰⁾	Male Rats, N=48, Group I (control), n=8 Group II (aronia juice), n=8	Chokeberry juice	10 mL/kg b.w./day	28 days		↓ TBARS, ↓ SOD, ↔ GSH, ↔ CAT, ↔ GPx, ↔ GR.	
Wei et al. (2017) ⁽⁴⁵⁾	Male Mice (6-8 weeks) N=60, Aged model group, n=12 Anthocyanins low dose group, n=12 Anthocyanins high dose group, n=12	Chokeberry extract	Low dose: 15 mg/kg b.w./day. High dose: 30mg/kg b.w./day.	8 weeks	↓ IL-1, ↓ COX-2, ↓ TGF-β1.	In serum: ↑ GSH-Px, ↑ T-SOD, ↔ MDA.	
Ma et al. (2022) ⁽²¹⁾	The male mouse model of pulmonary fibrosis, N=40, Group 3 (SP group), n=8 Groups 4 C3G (100 mg/kg), n=8 Group 5 C3G (200 mg/kg),	Chokeberry extract	100 and 200 mg/kg b.w. in distilled water/day	56 days		in lung tissue: ↑ SOD, ↑ GSH-Px ↓ MDA.	

	n=8						
Yang et al. (2020) ⁽⁴⁶⁾	Hepatic fibrosis male mice (6 weeks old), N=50, Model group, n=10 AMA high dose group (CCl4 + AMA-40), n=10 AMA low dose group (CCl4 + AMA-20), n=10	Chokeberry fruits	High dose group: 40 mg/kg. Low dose group: 20 mg/kg.	8 weeks	↓ IL-1, ↓ IL-6, ↓ COX-2, ↓ TNF- α .	↑ SOD, ↑ GSH.	
Piotrowska-Kempisty et al. (2020) ⁽²²⁾	Liver fibrosis rats model, N=48, Model group, n=8 Aronia, n=8	Chokeberry juice	100 mL/kg b.w./day	6 weeks	↔ TGF β , ↔ TNF α	↑ CAT, ↑ GPx, ↓ GST, ↓ TBARS, ↔ SOD, ↔ GR.	
Dąbrowski et al. (2020) ⁽⁵³⁾	Rat female model of cadm toxicity (3-4 weeks old), N=96, Model group CD ₁ i CD ₅ , n=16 Aronia group (AME + CD ₁), n=16 group, Aronia group (AME + CD ₅), n=16	Chokeberry extract	0.1% water solution of extract of polyphenols (AMPF) what mean no less than 51.7-104.6 mg/kg b.w/day	3 and 10 months		↔ GPx (after 3 months), ↑ GPx (after 10 months), ↑ CAT (after 3,10 months), ↑ GSH (after 3,10 months), ↑ SOD (after 3, 10 months), ↑ TAS (after 3, 10 months)	
Wang et al. (2020) numerals in parentheses	Mice male model of alcohol liver injury (8 weeks old), N=50, Model group n=10 AM group 0.5 g, n=10 Am group 2 g, n=10	Chokeberry fruit	500 or 2000 mg/kg/b.w./day	6 weeks	↓ IL-2, ↓ IL-4, ↓ IL-6.	↓ MDA, ↓ ROS, ↑ CAT, ↑ SOD, ↑ GSH-Px.	
Ciocoiu et al. (2013) ⁽²³⁾	Model of arterial hypertension rats, N=48, Model Group AHT (L-NAME 40mg/kg/b.w./day), n=12 Aronia group (AHT+	Chokeberry extract	5 mg/kg b.w/ every 2 days	8 weeks		↓ MDA, ↑ GSH-Px, ↑ GSH, ↑ TAC.	

Meżyńska et al. (2019) ⁽⁵⁵⁾	P), n=12 Rat female model of cadm toxicity (3-4 weeks old), N=192 Model group CD ₁ i CD ₅ , n=32 Aronia group (AME + CD ₁), n=32 group, Aronia group (AME + CD ₅), n=32	Chokeberry extract	63.1–159.1 mg/kg b. w./day	3, 10, 17, 24 months		↔ SOD (after 3, 10 months), ↑ SOD (after 17, 24 months), ↔ CAT (after 3,10,17 months), ↑ CAT (after 24 months), ↑ GPx (after 3,10,17,24 months), ↑ GR (after 3 and 24 months), ↔ GR (after 10,17 months), ↔ GSH (after 3 months) ↑ GSH (after 10,17, 24 months), ↓ GSSG (after 3,10,17, 24 months), ↓ H ₂ O ₂ (after 3,10,17, 24 months).	
Wang et al. (2019) ⁽⁴⁷⁾	Male rats (8-weeks old), N=60, Model group (group receiving colchicine), n=12 Aronia group, n=12	Chokeberry fruit	500 mg/kg b.w./day or 2000 mg/kg b. w./day	8 days	↓IL-1β, ↓IL-6, ↓IL-10, ↓TNF-α	↓ MDA, ↑ SOD, ↑ CAT, ↑ GSH-Px.	
Čujića et al. (2018) ⁽²⁴⁾	Rat male model of hypertension (6 months old), N=19, Model group, n=10 Aronia group, n=10	Chokeberry extract	50 mg/kg b.w./day	4 weeks (28 days)		↓ TBARS, ↓ SOD, ↔ GPx, ↔ CAT.	
Pavlova et al. (2024) ⁽³²⁾	Mice male and female (aged 3 months), N=24 Model group (DOX-treated), n=6 Aronia group (DOX+ aronia), n=6	Aronia extract	20% water solution	28 days		↑ GSH.	

Jiao et al. (2021) ⁽²⁵⁾	Male rats (5-weeks old), N=30, Model group (high-fat diet (HFD)), n=24 Aronia group low dose, n=6 Aronia group high dose, n=6	Powder (cyanidin-3-O-galactoside) from Aronia melanocarpa	100 and 200 mg/kg b.w./day	8 weeks	↓ TNF- α , ↓ IL-6, ↓ IL-1 β , ↓ NF- κ B.		
Jing et al. (2022) ⁽⁵⁶⁾	Hens, N=300, Control group n=60 Aronia 1% group, n=60 Aronia 4% group, n=60 Aronia 7% group, n=60	Chokeberry powder	diet supplemented with (1%, 4%, and 7%) concentrations of AM dried fruit powder of AM)	8 weeks		↓ MDA, ↑ SOD, ↑ GPx, ↑ TAOC, ↑ Nrf2.	
Valcheva-Kuzmanova et al. (2014) ⁽⁴⁸⁾	Male rats (age 4 months), N=96, Control group, n=24 Aronia 5mL group, n=24 Aronia 10 ml group, n=24	Chokeberry juice	5 mL/kg and 10 mL/kg		↓ IL-6, ↔ IL-10.	↔ MDA	
Liu et al. (2021) ⁽⁴²⁾	Pigs at weaned stage, N=96, Control group, n=24 Aronia 0,5‰ group, n=24 Aronia 1‰ group, n=24 Aronia 2 ‰ group, n=24	Aronia melanocarpa Pomace	0,5‰, 1‰ and 2‰ Aronia into the basal diet	28 days	↔ IgA, ↔ IgG, ↔ IgM.	↑ GSH-Px, ↔ SOD, ↔ CAT, ↔ TAOC.	
Yu et al. (2021) ⁽³³⁾	Mice, N=35, Control group (high-fat (HF)/high-sucrose (HS)), n=9 Aronia group (HF/HS+AM), n=10	Aronia berry extract powder	0,2% ARN powder in experimental diets	14 weeks	↓ NF-KB p65, ↓ TNF- α		
Ren et al. (2022) ⁽⁴⁰⁾	Growing pigs, N=27 Control group, (CON group), n=9 Aronia (AMP 4%) group, n=9	Chokeberry juice	4 or 8% Aronia of basic diet	7 weeks	↑ IgA, ↑ IgG, ↑ IgM, Jejunum: 4% Aronia:	Jejunum: ↑ TAOC, ↔ SOD, ↔ CAT, ↔ GSH,	↔ ACE, Chao1, Shannon, or Simpson phyla, ↓ <i>Proteobacteria</i> . 4% AMP significantly increased the: ↑ <i>Bacteroidetes</i>

	Aronia (AMP 8%) group, n=9				↓ IL-1 β , ↓IL-6, ↓IL-8, ↓IL-10, ↓TNF- α , Jejunal AMP: 8% ↓ IL-6, ↓IL-8, ↓IL-10, ↓TNF- α , ↔ IL-1 β .	↓ MDA. Serum changes without	↑ <i>Lachnospira</i> , ↑ <i>Solobacterium</i> , ↑ <i>Prevotella</i> , ↑ <i>Romboutsia</i> , ↑ <i>Butyrivibrio</i> , ↓ <i>Escherichia-Shigella</i> , ↓ <i>Pseudocardovia</i> , ↑ Zonulin 1, ↑ Claudin-1, ↑ Occludin. The 8% AMP: ↑ <i>Robinsoniella</i> , ↑ <i>Prevotella_9</i> , ↓ <i>Escherichia-Shigella</i> , ↓ <i>Pseudocardovia</i> , ↑ Zonulin 1, ↑ Claudin-1, ↔ Occludin.
Kim et al. (2013) ⁽²⁶⁾	Mice (8-week-old), N=20, Control group, n=10 Aronia 0,05% group, n=10 Aronia 0,005% group, n=10	Chokeberry extract	0.005% or 0.05% Aronia of basic diet	4 weeks		↑ PON-1, ↑ CAT, ↔ SOD, ↔ GPx.	
Jeong et al. (2017) ⁽²⁷⁾	The mouse model of D-galactose-induced aging, N=35, Model group, n=7 Aronia group, n=7	Chokeberry powder	0,5% or 1% Aronia of basic diet	8 weeks	↓ NF- κ B	↓ MDA, ↓ AGA, ↑ Nrf2.	
Ohgami et al. (2005) ⁽⁶³⁾	Rat male (8-week-old) Model (LPS induced uveitis) group, n=8 Aronia 1mg group, n=8 Aronia 10 mg group, n=8 Aronia 100 mg group, n=8	Chokeberry extract	1 mg, 10 mg, or 100 mg	Administered once intravenously	↓ TNF- α , ↓ NO.		

Song et al. (2018) ⁽²⁸⁾	Mouse male aging model (8-week-old), N=35, Model group, n=7 Aronia group, n=7	Chokeberry fruits	1% chokeberry of basic diet	8 weeks		↔ MDA (in serum), ↔ CAT, ↔ SOD, ↔ GPx.	
Zhao et al. (2021) ⁽³⁴⁾	The aging mice male model (6–8 weeks old), N=40 Model group, n=10 Aronia 100 mg group, n=10 Aronia 200 mg group, n=10		100 and 200 mg/kg b.w./day	6 weeks	↓ NF-κB, ↓ IkB-α.	↓ MDA, ↑ SOD, ↑ CAT, ↑ Nrf2, ↑ HO-1.	↑ <i>Bacteroides</i> , ↓ <i>Firmicutes</i> .
Zhu et al. (2022) ⁽⁵¹⁾	The rat model of obesity N=28 Model (high-fat diet HFD) group, n=8 Aronia group, n=10	Chokeberry extract	1000 mg/kg b.w./day	40 days			↔ ACE, Chao1, Shannon and Simpson ↓ F/B <i>Phylum</i> ↑ <i>Bacteroidetes</i> , ↑ <i>Verrucomicrobia</i> ↓ <i>Firmicutes</i> Genus level, ↑ <i>Akkermansia</i> , ↑ <i>Bacteroides</i> , ↑ <i>Romboutsia</i> , ↓ <i>Lachnospiraceae</i> , ↑ ↓ <i>Clostridium</i> , ↓ <i>Desulfovibrio</i> , ↓ <i>Lachnoclostridium</i> .
Brzóska et al. (2016) ⁽⁵⁷⁾	Cadm intoxicity rat model, N=192 Model group CD ₁ i CD ₅ , n=32 Aronia group (AME + CD ₁), n=32 Aronia group (AME + CD ₅), n=32	Aronia powder	0.1% aqueous solution	3, 10, 17, and 24 months		In the serum: ↑TAS (after 3,10,17, 24 months), ↓ TOS (after 3,10, 17, 24 months). In the bone: ↑TAS (after 3,10 months), ↔ TAS (after 17, 24 months), ↔ TOS (after 3,10 months) ↓ TOS (after 17,24 months), ↑ GPx (after 3,10,17,24 months), ↓ GR (after	<i>Prevotella</i> ,

						3,10,17, 24) ↑ SOD (after 3,10,17,24 months), ↑ CAT (after 3,10,17,24 months), ↓ H ₂ O ₂ (after 3,10,24 months).	
Faff and Frankiewicz-Józko (2003) ⁽⁴⁹⁾	Male rats exercise model N=60, control-exercise (CE) group, n=15 Aronia (AM-fed-exercise (AE)), n=15	Chokeberry extract	0.7 mg× kg-1 body mass 1:10 water solution	4 days		↔ TBARS ↑ GSH in heart and the red portion of the gastrocnemius muscle	
Lipińska et al. (2017) ⁽²⁹⁾	Polish Merino lambs N=48, Control group, n=16 Aronia 150 g group, n=16 Aronia 300 g group, n=16	Chokeberry pomace	150 g or 300 g of chokeberry pomace/ kg of the complete compound feed/day	90 days		↓ SOD, ↑ GPx, ↑ GSH.	
Gajic et al. (2020) ⁽⁶²⁾	Mice male (2 months old) N=21, Control group, n=7 Aronia 50 mg group, n=7 Aronia 200 mg group, n=7	Chokeberry Extract	200 mg/kg b.w. or 50 mg/kg b.w./day	7 days	↑ IFN-γ, ↔ IL-17.		
Onopiuk et al. (2021) ⁽⁵⁰⁾	Cadm intoxicity rat female model (3-4week-old) N=96, Model group CD ₁ i CD ₅ , n=16 Aronia group (AME + CD ₁), n=16 Aronia group (AME + CD ₅), n=16	Chokeberry Extract	0.1% aqueous extract from chokeberrie ranged from 78.70mg/kg b.w. to 153.82mg/kg b.w./day	3, 10 months		↔ CAT, ↑ TAS (after 3,10 months), ↓ TOS (after 3,10 months in AME + CD ₅), ↔ TOS (after 3 months in AME + CD ₁) ↑ SOD (after 3,10 months in AME + CD ₅), ↔ SOD (after 3 months in AME + CD ₁) ↑ CAT (after 3,10 months in AME + CD ₅),	

						↔ CAT (after 10 months in AME + CD ₁) ↑ GPx (after 3,10 months) ↑ GSH (after 3,10 months in AME + CD ₅), ↔ GSH (after 3 months in AME + CD ₁) ↔ H ₂ O ₂ (after 3 months) ↓ H ₂ O ₂ (after 10 months)	
Valcheva-Kuzmanova et al. (2005) ⁽¹⁹⁾	Rat model of gastric mucosal damage, N= 48, Model group, n=6 Aronia 5 mL group, n=6 Aronia 10 mL group, n=6 Aronia 20 mL group, n=6	Chokeberry juice	5, 10 or 20mL/kg b.w	1 dose		↔ MDA, ↔ GSH, ↔ GSSG.	
Mężyńska et al. (2018) ⁽⁵⁸⁾	Rat female model of cadm toxicity (3-4 weeks old), N=192, Model group CD ₁ i CD ₅ , n=32 Aronia group (AME + CD ₁), n= 32 Aronia group (AME + CD ₅), n=32	Chokeberry extract	63.1 to 159.1 mg/kg b.w/day	3, 10, 17, and 24 months		↔ SOD (after 3,10 months), ↑ SOD (after 17, 24 months), ↔ CAT (after 3,10,17 months), ↑ CAT (after 24 months), ↑ GPx (after 3,10, 17, 24 months), ↑ GR (after 3, 24 months), ↔ GR (10, 17 months), ↑ GSH (after 10, 17, 24 months), ↔ GSH (after 3 months), ↓ GSSH (after 3,10, 17, 24 months).	

Dąbrowska et al. (2019) ⁽⁵²⁾	Cadm model of toxicity (3-4 weeks old) N=96, Rat female model of cadm toxicity (3-4 weeks old), N=96, Model group CD ₁ i CD ₅ , n=16 Aronia group (AME + CD ₁), n=16, Aronia group (AME + CD ₅), n=16	Chokeberry extract	51.7 to 104.6 mg/kg b.w./day	3 and 10 months		↔TAS (after 3 months) ↑ TAS (after 10 months) ↑ CAT (after 3, 10 months) ↑ SOD (after 3, 10 months) ↑ GPx (after 3, 10 months) ↔GSH (after 3, 10 months).	
Xing et al. (2023) ⁽³⁶⁾	Rat male model of age-related macular degeneration, N=40 Model group, n= 10 Aronia (AAE) group, n = 10	Chokeberry extract	600 mg/kg b. w./day in distilled water was administrated	28 days		↔ CAT, ↔ SOD, ↑ GPx, ↓ MDA.	↓ Chao1 index ↓ Simpson index ↔ Lactobacillus, ↔ Alistipes, ↔ Para bacteroides, ↔ Akkermansia, ↔ Escherichia, ↔ Parasutterella.
Liu et al. (2023) ⁽³⁷⁾	Mouse female model of PM (particulate matter in the atmosphere), N=40 Model group, n=8 Aronia group 3 (PM10+ C3G 75), n=8 Aronia group 4 (PM10+C3G150), n=8 Aronia Group 5 (PM10+C3G300)	Cyanidin-3-galactoside extract	75mg/kg b.w/day or 150 mg/kg b.w/day or 300mg/kg b.w./day	28 days	↓ IL-1β, ↓ IL-6, ↓ TNF-α.		
Wei et al. (2023) ⁽⁵⁴⁾	Mice male model of alcoholic liver disease (ALD), N=80 Model group (42% alcohol), n=10 Aronia (Low-dose AMA) group, n=10 Aronia (High-dose AMA) group, n=10	Chokeberry fruits	20 mg/kg b.w/day or 40 mg/kg b.w/day	8 weeks	↓ IL-1, ↓ TNFα, ↓ IL-6.	↑ GHS-Px, ↓ HO-1, ↑ Nrf2.	

Wang et al. (2023) ⁽⁵⁹⁾	1. Crabs long-term ammonia exposure, N=600 Aronia (AME1) group, n=25 Aronia (AME3) group, n=25 Aronia (AME5) group, n=25 2. Crabs after acute ammonia exposure, N=300 Aronia (AME3) group, n=25	Chokeberry extract	1 %, 3 %, and 5 % Aronia of basic diet	4 weeks		long-term ammonia exposure: ↓ MDA, ↑ CAT, ↑ SOD, acute ammonia exposure: ↓ MDA, ↑ CAT, ↑ SOD.	
Smereczński et al. (2023) ⁽⁶⁰⁾	Rat female model of cadm toxicity (3-4 weeks old), N=192 Model group CD1 i CD5, n=32 Aronia group (AME + CD ₁), n=32, Aronia group (AME + CD ₅), n=32	Chokeberry extract	0.1% aqueous solution (1 g of the powdered extract was dissolved in 1 L water)	3, 10, 17 and 24 months		in the kidney: ← TAS (after 3,10, 17, 24 months), ← TOS (after 3,10, 17 and months) ↓ TOS (after 24 months) ↑ CAT (after 3, 17, 24 months) ← CAT (after 10 months) ← SOD (after 3 months) ↑ SOD (after 10, 17, 24 months), ← GPx, ← GR (after 3, 10, 17 months), ↓ GR (after 24 months), ← GSH, ← GSSG, ← H ₂ O ₂ .	
Ruczaj et al. (2024) ⁽⁶¹⁾	Rat female model of cadm toxicity (3-4 weeks old), N=192 Model group CD1 i CD5, n=32 Aronia group (AME + CD ₁), n=32, Aronia group (AME + CD ₅), n=32	Chokeberry extract	0,1 % Aronia into the basal diet	3,10,17 and 24 months		↑ CAT (after 3,10, 17, 24 months), ↔ SOD (after 3 months), ↑ SOD (after 10,17, 24 months), ↔ GPx (after 3, 10 months), ↑ GPx (after 17, 24 months),	

						↔ GR (after 3,10), ↓ GR (after 17,24 months), ↔ GSH (after 3 months), ↑ GSH (after 10,17, 24 months), ↔ GSSG (after 3,10, 17 months), ↓ GSSG (after 24 months), ↔TOS (after 10 months), ↓ TOS (after 3, 17, 24 months), ↔TAS (after 3,10 months), ↑ TAS (after 17, 24 months), ↔ H ₂ O ₂ (after 3 months), ↓ H ₂ O ₂ (after 10,17, 24 months).	
Wilson et al. (2023) (38)	Mice N=14, Control (sugar-matched juice) CON _{LO} , n = 3, CON _{HI} , n = 3. Aronia ARO _{LO} , n = 3, ARO _{HI} , n = 5 LO-Low inflammation HI- High inflammation	Chokeberry juice	150 ml juice/ week per cage	8 weeks			↑ Shanon index, ↑ <i>Eisenbergiella</i> , ↑ <i>Faecalibacillus</i> , ↑ <i>Faecalibacillus</i> , ↑ <i>Howardella</i> , ↑ <i>Eggerthellaceae</i> .
Doma et al (2023) (39)	Rat N=40, Control group, n =10, Aronia (CA) group, n=10	Chokeberry extract	6 % aqueous extract as drinking water	4 weeks		↔ CAT, ↔ SOD, ↔TBARS, ↔GPx ↔GSH, ↔ GSH-r.	

Abbreviations: ↔ No change, ↓ Decrease, ↑ Increase, ≠ Not homogeneous, b.w. body weight ; ACE: Abundance-based coverage estimator, CAT: catalase, COX-2: cyclooxygenase-2, ChaO1: , CRP: C-reactive protein, GPx: glutathione peroxidase, GR: glutathione reductase, GSH-r: glutathione reductase, GSH: reduced glutathione, GST: glutathione transferases, GSH-Px: glutathione peroxidase, GSSG: oxidized glutathione, H₂O₂: hydrogen peroxide, IgA: immunoglobulin A, IgG: immunoglobulin G, IgM: immunoglobulin M, F/B ratio: Firmicutes/Bacteroides ratio, TLR4: Toll-like receptor 4, PI3HO-1: Heme oxygenase-1, IL-1, interleukin-1, IL-1β: interleukin 1β, IL-6: interleukin 6, LPO: lipid peroxides, NOS: nitric oxide synthase, MDA: malondialdehyde, MCP-1: monocyte chemoattractant protein-1, Nrf2: nuclear related factor-2, NF-κB Nuclear factor kappa-B, OH: hydroxyl groups, PI3K: P-phosphatidylinositol-3-hydroxykinase, PCoA: Principal coordinate analysis, PGE2: prostaglandin E2, ROS: reactive oxygen species, SOD: superoxide dismutase, TAC: total antioxidant capacity, T-AOC: total antioxidant capacity, TGF-β1, transforming growth factor-β1, TAS: total antioxidative status, TBARS: thiobarbituric acid reactive substances, TNFα: tumor necrosis factor α, TOS: total oxidative, NO: nitric oxide.

Table 5. Summary of studies on the effects of chokeberry on inflammation, oxidative stress and intestinal parameters – human.

Author	OCMB	Group	Supplement	Dose	Duration of supplementation	Markers of inflammation	Markers of oxidative stress	Changes in gut microbiota
Duchnowicz et al. (2012) ⁽¹¹⁾	1 level	Patients with hypercholesterolemia, no pharmacological treatment, N=45 (males, females), Aronia, n=25 (55.9±7.4 y), Control, n=20 (50.3±8.2 y).	<i>Aronia melanocarpa</i> extract	300 ml/day (100 mg three times a day)	2 months		↓ TBARS	
Broncel et al. (2010) ⁽⁶⁴⁾	1 level	Patients with metabolic syndrome, N=47 (32 females, 15 males, 42-65 y), Aronia, n=25, Control, n=22.	<i>Aronia melanocarpa</i> extract	300 ml/day (100 mg three times a day)	2 months	↔ CRP	↓ TBARS ↑ GSH-Px ↑ SOD (after 1 month) ↔ SOD (after 2 months) ↓ CAT (after 1 month)	
Stankiewicz et al. (2021) ⁽⁷⁾	1 level	Young football players, N=20 (males, 15.8± 0.7 y), Aronia, n=12, Control, n=8.	Chokeberry juice	200 ml/day (100 ml twice a day)	7 weeks	↔ IL-6 ↔ myoglobin	↔ 8-OHdG ↔ TAC ↔ TBARS	
Petrovic et al. (2016) ⁽⁶⁶⁾	1 level	Handball players, N=32 (males 18.5±1.06 y; females 17.2±0.93 y), Aronia, n= 18 (8 males, 10 females, 18.5±1.06 y), Control, n=14 (7 males, 7 females).	Chokeberry juice	100 ml/day	4 weeks		Male: ↓TBARS Female: ↔TBARS	

Skarpańska-Stejnborn et al. (2014) ⁽⁶⁾	1 level	Elite rowers, N=19 (males), Aronia, n=10 (20.5±0.97 y), Control, n=9 (20.8±1.09 y).	Chokeberry juice	150 ml/day (50 ml three times a day)	8 weeks	↔IL-6 ↓ TNF- α	↑ TAC	
Xie et al. (2016) ⁽⁶⁷⁾	1 level	Former smokers, N=49 (males, females), Aronia, n=25 (32.6±2.6 y), Control, n=24 (37.4±3.0 y).	Chokeberry extract	500 mg/day (250 mg twice a day)	12 weeks	↔ IL-6 ↔ IL-1 β ↔ TNF- α ↔ CRP ↔ MCP-1	↔ CAT ↔ GPx, ↔ SOD	
Pilaczynska-Szcześniak et al. (2005) ⁽⁶⁵⁾	1 level	Elite rowers, N=19 (males), Aronia, n=9 (21±0.8 y), Control, n=10 (22±1.7 y).	Chokeberry juice	150 ml/day (50 ml three times a day)	4 weeks		↓ TBARS, ↓ GPx, ↓ SOD.	
Istas et al. (2019) ⁽⁷⁰⁾	1 level	Healthy males, N=66, Aronia extract, n=23, (24±6.3 y), Aronia whole fruit powder, n= 23, (24±5.2 y), Control, n=20.	Aronia extract, Aronia whole fruit powder.	500 mg/day	12 weeks			Aronia extract/whole fruit: ↔ alfa-diversity ↔ beta diversity Aronia extract: ↑ <i>Anaerostipes</i> Aronia whole fruit: ↑ <i>Bacteroides</i>
Le Sayec et al. (2022) ⁽¹²⁾	1 level	Prehypertensive participants, N=102 (47 males, 55 females), Aronia, n=51 (56.2±8.7 y), Control, n=51 (56.2±9 y)	Aronia extract	500 mg/day	12 weeks			↔ Shannon-Wiener index, ↔ Simpson index, ↔ Bray-Curtis, ↑ <i>Intestinimonas butyriciproducens</i> , ↑ <i>Lawsonibacter asaccharolyticus</i> , ↑ <i>Butyricimonas faecihominis</i> , ↑ <i>Bacteroides xylanisolvens</i> , ↓ <i>Senegalimassilia anaerobia</i> , ↓ <i>Haemophilus</i>

								<i>parainfluenzae</i> .
Chung et al. (2023) ⁽⁶⁸⁾	1 level	Healthy adults, N=70, (35 males, 35 females), Aronia, n=35 (45.0±1.3 y) Control, n=35 (46.5±1.3 y)	Aronia berry extract	300 mg/ day (150 mg twice a day)	8 weeks	↑ IL-6 Immediately post-exercise	↓ GSH 30 min post-exercise, ↓ GPx immediately and 30 min post-exercise, ↓ GSSG 30 min post-exercise, ↔ CAT 30 min post-exercise, ↔ SOD 30 min post-exercise, ↔ MDA 30 min post-exercise.	
Lackner et al. (2024) ⁽⁶⁹⁾	1 level	Normal weight females, N=40 (18-40 y) Aronia, n=20 Placebo, n=20	Aronia juice	200 ml/day (100 ml twice a day)	6 weeks			↔ Shannon index
Stankiewicz et al. (2023) ⁽¹³⁾	1 level	Semi-professional male football players, N=22 Aronia, n=10 (19.86 ± 0.61 y) Placebo, n=12 (20.05 ± 0.52 y)	Chokeberry extract	6 g of lyophilized extract (in capsules)/day	90 days	↓ IL-6 ↑ IL-10	↑ TAC, ↓ 8-OHdG.	

Abbreviations: ↔ No change, ↓ Decrease, ↑ Increase; 8-OHdG: 8-hydroxy-2'-deoxyguanosine, CAT: catalase, CRP: C-reactive protein, GPx: glutathione peroxidase, GR: glutathione reductase, GSH: reduced glutathione, GSH-Px: glutathione peroxidase, GSSG: oxidized glutathione, IL-1β: interleukin 1β, IL-6: interleukin 6, MCP-1: monocyte chemoattractant protein-1, MDA: malondialdehyde, SOD: superoxide dismutase, TAC: total antioxidant capacity, T-AOC: total antioxidant capacity, TAS: total antioxidative status, TBARS: thiobarbituric acid reactive substances, TNFα: tumor necrosis factor α.